CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization Increased Risk of Valvular Heart Disease in Systemic Sclerosis: An Underrecognized Cardiac Complication A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis Intravascular Ultrasound and Angioscopy Assessment of Coronary Plaque Components in Chronic Totally Occluded Lesions Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation Transcatheter Aortic Valve Replacement in Low-risk Patients With Bicuspid Aortic Valve Stenosis Coronary plaque redistribution after stent implantation is determined by lipid composition: A NIRS-IVUS analysis Identifying coronary artery disease patients at risk for sudden and/or arrhythmic death: remaining limitations of the electrocardiogram Serial intravascular ultrasound assessment of very late stent thrombosis after sirolimus-eluting stent placement

Original ResearchVolume 12, Issue 24, December 2019

JOURNAL:JACC Cardiovasc Interv. Article Link

Association Between Diastolic Dysfunction and Health Status Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement

AO Malik, M Omer, MC Pflederer et al. Keywords: health status; left ventricular diastolic dysfunction; TAVR

ABSTRACT

OBJECTIVES - The aim of this study was to assess the association of baseline left ventricular diastolic dysfunction (LVDD) with health status outcomes of patients undergoing transcatheter aortic valve replacement (TAVR).

 

BACKGROUND - Although LVDD in patients with aortic stenosis is associated with higher mortality after TAVR, it is unknown if it is also associated with health status recovery.

 

METHODS - In a cohort of 304 patients with interpretable echocardiograms, undergoing TAVR, LVDD was categorized at baseline as absent (grade 0), mild (grade 1), moderate (grade 2), or severe (grade 3). Disease-specific health status was assessed using the 12-item Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OS) at baseline and at 1-month and 12-month follow-up. Association of baseline LVDD with health status at baseline and follow-up after TAVR was assessed using a linear trend test, and association with health status recovery (change in KCCQ-OS) was examined using a linear mixed model adjusting for baseline KCCQ-OS.

 

RESULTS - Twenty-four (7.9%), 54 (17.8%), 186 (61.2%), and 40 (13.2%) patients had LVDD grades of 0, 1, 2, and 3, respectively. Baseline KCCQ-OS was 61.3 ± 22.7, 51.0 ± 26.1, 44.7 ± 25.7, and 44.4 ± 21.9 (p = 0.004) in patients with LVDD grades of 0, 1,2 and 3. At 1 and 12 months after TAVR, LVDD was not associated with KCCQ-OS. Recovery in KCCQ-OS after TAVR was substantial and similar in patients across all severities of LVDD.

 

CONCLUSIONS - Although LVDD is associated with health status prior to TAVR, patients across all severities of LVDD have similar recovery in health status after TAVR.